Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
July 25, 2017 6:30 AM EDTCompany provides update on long-term growth strategy
SPINRAZA approved in Europe, Japan, and Canada for spinal muscular atrophy
Company acquires Phase-3 ready stroke asset from Remedy Pharmaceuticals
Company completes exclusive license agreement with Bristol-Myers Squibb for Phase-2 anti-tau antibody with potential in Alzheimers disease and progressive supranuclear palsy
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2017 financial results, including:
Total revenues of $3.1 billion, a 6% increase versus the prior year and a 15%... More